If enacted, HB 139 would amend Chapters 431 and 432 of the Hawaii Revised Statutes to include provisions for fertility preservation services. This change would legally require insurers, mutual benefit societies, and health maintenance organizations to cover fertility preservation, thus directly impacting insurance practices and benefitting those at risk of infertility due to medical treatments. The statute also sets forth specific regulations to prevent restrictions based on a patient's medical history or health condition, aiming for equitable access to required services.
House Bill 139 proposes to mandate insurance coverage for standard fertility preservation services for insurance policies issued or renewed in Hawaii after December 31, 2025. This bill specifically targets individuals facing medically necessary treatments that may result in iatrogenic infertility, such as chemotherapy or radiation treatments related to cancer care. It aims to ensure that policyholders, along with dependents under age twenty-six, are provided access to these critical services without discrimination or prior condition exclusions.
The sentiment surrounding HB 139 appears to be generally positive among proponents, particularly advocates for reproductive health and cancer care, who emphasize the importance of preserving fertility for individuals undergoing treatments that pose risks to their reproductive health. There may be concerns from some stakeholders about potential cost implications for insurance providers and the overall impact on insurance premiums, although advocates argue that these services are essential for patient care.
Notable points of contention may arise regarding the implementation of the bill, particularly around what constitutes 'standard' fertility preservation services, and the financial responsibility placed on insurers. There may be debates on how this will affect insurance premiums and availability of fertility-related services, as well as discussions on ensuring that other necessary health services are not compromised in the face of added coverage requirements. Furthermore, there could be discussions about the exclusions for experimental procedures and third-party assisted reproduction technologies.